Concurrent chemotherapy with intensity‐modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: A retrospective single‐institution analysis

Saba, Nabil F.; Edelman, Scott; Tighiouart, Mourad; Gaultney, J; Davis, Lawrence W.; Khuri, Fadlo R.; Chen, Amy; Grist, William; Shin, Dong M.

doi:10.1002/hed.21120

Cited by 16 publications

(13 citation statements)

References 28 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9,10 As training in this specialized form of treatment increases among head and neck radiation oncologists, more institutions are reporting their treatment outcomes and toxicities for this technique. Our disease outcomes are similar to those of previously published series, [11][12][13][14][15][16][17][18][19][20] demonstrating high rates of LC and LRC with distant metastasis being the predominant pattern of failure. Like the current series, most of these reports are single-institution retrospective reviews, which remain our main source of data regarding the use of IMRT for SCC of the oropharynx despite their potential drawbacks.…”

Section: Discussionsupporting

confidence: 89%

Intensity‐modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Intensity‐modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Similar results are reported with concurrent chemotherapy and intensity-modulated radiation therapy, but including a mixed oropharyngeal and laryngeal material and yielding a 3 year overall survival rate of 81.2% [20]. …”

Section: Discussionsupporting

confidence: 75%

Surgery and postoperative radiotherapy a valid treatment for advanced oropharyngeal carcinoma

Lybak

Liavaag

Olofsson

2010

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Since 1992 we have prospectively included all head and neck cancer patients in our health region in a departmental based register. Our hospital takes care of all head and neck cancer patients in our health region consisting of approximately 1 million people. In 1997, we evaluated the results of the treatment of oropharyngeal cancer in the 1992–1997 period. On the basis of this evaluation, we changed our treatment policy for tonsillar and base of tongue carcinoma. We first changed the treatment for the lesions with worst prognosis, i.e., those with T3–T4 carcinomas, from radiotherapy only, to radical surgery and postoperative radiotherapy. We have since that time increasingly also operated the smaller oropharyngeal carcinomas. The 2 years’ overall survival and disease-specific survival for all patients diagnosed in the 1992–1997 period was 56 and 63%, respectively. The results from a similar group of patients in the 6 years’ period from 2000 to 2005, after the change in treatment, have increased to 83 and 88%. When we looked at the subgroup of patients in the 2000–2005 period treated with surgery and postoperative radiotherapy, 45 out of 69 patients (65%) presenting with an oropharyngeal cancer were fit for operation. With radical surgery and postoperative radiation therapy, the 2 years overall survival is now 91%. The 2-year disease-specific survival is 96% and the locoregional control is 98%. This is a marked improvement as compared to radiotherapy alone and definitely competitive with modern radiochemotherapy.

show abstract

“…Our results are clearly inferior to those reported by several American groups [35][36][37][38][39][40][41][42] but are in line with those reported from institutions in Europe [43][44][45]. The causes of these differences are merely speculative, but most likely they are both patient and tumour related.…”

Section: Discussioncontrasting

confidence: 68%

Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience

Gestel¹,

Weyngaert²,

Schrijvers³

et al. 2011

BJR

View full text Add to dashboard Cite

Methods: Patients with early and locoregionally advanced HNC were treated with inverse-planned step-and-shoot IMRT. The prescribed dose varied from 66 Gy to 70 Gy in those receiving IMRT as definitive treatment and from 60 Gy to 70 Gy in the postoperative setting. IMRT was given alone, after induction chemotherapy (ICT), with concomitant chemotherapy (CRT) or with both. Acute and late toxicities are reported; locoregional control (LRC), locoregional relapse-free survival (LRRFS) and overall survival (OS) were calculated from the start of radiation. Results: IMRT was used in 78 patients (48 as definitive treatment, 30 post-operatively), of whom 20 also received ICT and 35 CRT. Three patients stopped IMRT early, one for toxicity (mucosa). Acute toxicity scoring revealed 5 cases (6%) of severe skin toxicity and 65 cases (83%) of severe mucosal toxicity. After a median follow-up of 18.7 months, late toxicities included xerostomia (44%), loss of taste (14%) and fibrosis of the neck (9%). 16 patients had died, of whom 10 due to tumour recurrence/progression and 2 due to treatment (but not IMRT related). The LRC, LRRFS and OS at 3 years are 66.1%, 48.5% and 60.3% in the definitive IMRT group and 85.4%, 82.5% and 85.9% in the postoperative setting, respectively. Conclusion: We consider IMRT for locoregional HNC feasible not only as a single modality but also after surgery, after induction chemotherapy and concurrently with chemotherapy.

show abstract

Concurrent chemotherapy with intensity‐modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: A retrospective single‐institution analysis

Abstract: This retrospective analysis reveals a very good outcome and an acceptable toxicity profile for patients with locally advanced SCC of the oropharynx and larynx treated with chemotherapy and IMRT concurrently.

Cited by 16 publications

References 28 publications

Intensity‐modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma

Intensity‐modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma

Surgery and postoperative radiotherapy a valid treatment for advanced oropharyngeal carcinoma

Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience

Contact Info

Product

Resources

About